The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers

• Denis Malvy ,

  * E-mail: denis.malvy@chu-bordeaux.fr

  Affiliations Inserm 1219, University of Bordeaux, Bordeaux, France, Department for Infectious and Tropical Diseases, University Hospital Center of Bordeaux, Bordeaux, France

  http://orcid.org/0000-0003-1948-9355

  ⨯
• Anne-Marie Taburet,

  Affiliation UMR1184, Inserm, CEA, University Paris Saclay, Le Kremlin-Bicêtre, France

  ⨯
• Xavier de Lamballerie,

  Affiliation IRD 190, Inserm1207, University Aix-Marseille, Marseille, France

  ⨯
• France Mentre,

  Affiliation IAME, Inserm, University of Paris, Paris, France

  http://orcid.org/0000-0002-7045-1275

  ⨯
• Fabrice Extramiana

  Affiliation CNMR, Maladies Cardiaques Héréditaires Rares & Department of Cardiology, AP-HP, Université de Paris, Paris, France

  ⨯